Suchergebnisse - "Curigliano, G"

PubPharm (27)

1

Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Tarantino, P. | Tolaney, S. | Curigliano, G.

CommentOn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869

2

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Curigliano, G. | Dunton, K. | Rosenlund, M. | +5

3

Targeting HER3 for cancer treatment : a new horizon for an old target

enthalten in: ESMO open | 2023

von Uliano, J. | Corvaja, C. | Curigliano, G. | +1

4

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy : update from the ARROW trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Griesinger, F. | Curigliano, G. | Thomas, M. | +23

CommentIn: Nat Rev Clin Oncol. 2022 Oct;19(10):615. - PMID 35999290

5

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Passaro, A. | Leighl, N. | Blackhall, F. | +31

6

How I treat HER2-positive early breast cancer : how long adjuvant trastuzumab is needed?

enthalten in: ESMO open | 2022

von Morganti, S. | Bianchini, G. | Giordano, A. | +3

7

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) : final overall survival analysis

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Curigliano, G. | Mueller, V. | Borges, V. | +17

ErratumIn: Ann Oncol. 2023 Jul;34(7):630. - PMID 36564285

8

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Miles, D. | Ciruelos, E. | Schneeweiss, A. | +116

CommentIn: Ann Oncol. 2021 Oct;32(10):1206-1208. - PMID 34403778

9

Clinical development and current role of margetuximab for the treatment of breast cancer

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2021

von Tarantino, P. | Uliano, J. | Morganti, S. | +3

10

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Belli, C. | Penault-Llorca, F. | Ladanyi, M. | +13